Advertisement

PentaVision

Retinal Physician

Article

Candidate Selection and Practice Management Considerations With Anticomplement Therapy for GA

We are no longer at the mercy of the disease, but we must still think about increases in patient volume.

By: Anton Kolomeyer, MD, PhD
Retinal Physician February 7, 2025

Clinical Scorecard: Candidate Selection and Practice Management Considerations With Anticomplement Therapy for GA

At a Glance

CategoryDetail
ConditionGeographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD)
Key MechanismsAnticomplement therapy via intravitreal injections
Target PopulationPatients with GA secondary to AMD, including asymptomatic individuals
Care SettingOphthalmology clinics

Key Highlights

  • Anticomplement therapy offers a new treatment option for GA after decades of limited options.
  • All patients with GA secondary to AMD are potential candidates for therapy, regardless of visual acuity.
  • Patient discussions about therapy often hinge on the status of the fellow eye.
  • Increased patient volume may challenge practice management and clinic resources.
  • Long-term injections are required every 4 to 8 weeks for GA management.

Guideline-Based Recommendations

Diagnosis

  • Assess visual acuity and the status of both eyes in patients with GA.

Management

  • Educate patients about the natural course of GA and available treatment options.

Monitoring & Follow-up

  • Consider close observation for asymptomatic patients with good vision.

Risks

  • Potential for increased clinic workload and resource constraints due to higher patient volumes.

Patient & Prescribing Data

Patients with geographic atrophy secondary to AMD

Therapy may be initiated based on the visual status of the fellow eye.

Clinical Best Practices

  • Allocate sufficient clinic time for patient education and discussions about therapy.
  • Prepare for logistical challenges related to increased patient volume and treatment administration.

References